# A Phase Ⅲ Clinical Study Trial of Felbinac Trometamol Injection in China

> **NCT04526132** · PHASE3 · COMPLETED · sponsor: **Shijiazhuang Yiling Pharmaceutical Co. Ltd** · enrollment: 306 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Felbinac Trometamol Injection
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04526132
- **Lead sponsor:** Shijiazhuang Yiling Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-25
- **Primary completion:** 2021-12-29
- **Final completion:** 2022-06-30
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2023-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526132, "A Phase Ⅲ Clinical Study Trial of Felbinac Trometamol Injection in China". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04526132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*